Showing 3581-3590 of 9296 results for "".
- Merz CEO Focused on Advancing the Companyhttps://practicaldermatology.com/news/20120515-merz_ceo_focused_on_advancing_the_company/2459801/William “Bill” Humphries, newly appointed CEO of Merz, Inc., has been setting the record straight. For example, addressing a recent injunction that bars the marketing of Xeomin for aesthetic indications, he insists, “the impact of the injunction isn't dramatic.” As a private company with more than …
- Ouchless Needle Announces First Exclusive International Distribution Agreement with Device Technologieshttps://practicaldermatology.com/news/20120501-ouchless_needle_announces_first_exclusive_international_distribution_agreement_with_device_technologies/2459811/Ouchless Needle by the BellaNovus Development Company announced their first international exclusive distribution agreement with Device Technologies for Australia and New Zealand. Developed by aesthetic plastic surgery innovator Marc J. Salzman, MD, FACS, the Ouchless Needle Collection is a disposa…
- PreCision Dermatology Acquires Assets of Triax Pharmaceuticalshttps://practicaldermatology.com/news/20120430-precision_dermatology_acquires_assets_of_triax_pharmaceuticals/2459813/PreCision Dermatology has acquired the assets of Triax Pharmaceuticals LLC, a specialty pharmaceutical company with products including the mid-potency topical steroid Locoid, as well as Minocin and Tretin-X. Onset Dermatologics, the prescription dermatology subsidiary of PreCision Dermatology, will…
- Ulthera Cleared in Mexicohttps://practicaldermatology.com/news/20120320-ulthera_cleared_in_mexico/2459837/Ulthera is now registered in Mexico to market and distribute its ultrasound therapy device, the Ulthera System. In Mexico, the system is now prescribed to produce stimulation in tissues to raise the temperature in a localized manner for aesthetic, non-invasive use, according to the company. The Ult…
- Judge Blocks Launch of Xeomin for Aesthetic Indicationshttps://practicaldermatology.com/news/20120307-judge_blocks_launch_of_xeomin_for_aesthetic_indications/2459852/The planned March 12 launch of Merz's Xeomin (incobotulinumtoxinA) for aesthetic indications will almost certainly be delayed due to a court order blocking marketing of incobotulinumtoxinA. The order comes in response to a suit by Allergan , alleging that its trade secrets related to Botox (onabot…
- FDA Approves Methoxsalen USP Providerhttps://practicaldermatology.com/news/20120229-fda_approves_methoxsalen_usp_provider/2459859/FDA has approved a secondary supplier of Methoxsalen USP, prescribed under the brand name Oxsoralen-Ultra® (methoxsalen) Capsules, USP, 10mg. Valeant Dermatology, a division of Valeant Pharmaceuticals North America LLC, and marketer of the drug announced the decision last month. Questions or con…
- Health Canada Approves BMS' Yervoy for Melanomahttps://practicaldermatology.com/news/20120208-health_canada_approves_bms_yervoy_for_melanoma/2459869/Health Canada approved Yervoy (ipilimumab 3mg/kg, Bristol-Myers Squibb) for the treatment of unresectable or metastatic melanoma in patients who have failed or do not tolerate other systemic therapy for advanced disease. Yervoy was approved by the FDA for US marketing last year. According to submis…
- American Academy of Dermatology Issues Updated Guidelines for the Management of Acnehttps://practicaldermatology.com/news/american-academy-of-dermatology-issues-updated-guidelines-for-the-management-of-acne/2462235/Acne is the most common skin condition in the United States, affecting nearly 50 million Americans each year, with symptoms usually beginning in puberty. Acne affects 85% of adolescents and can also often begin or continue in adulthood, especially in women. To help ensure that people with acne get …
- UCSF Apologizes for Dermatology Experiments in Prisoners in 1960shttps://practicaldermatology.com/news/ucsf-apologizes-for-dermatology-experiments-in-prisoners-in-1960s/2461477/The University of California, San Francisco apologized for conducting unethical dermatology experiments on at least 2,600 incarcerated men in the 1960s and 1970s. Experiments included putting pesticides and herbicides on the men’s skin and injecting it into their veins. Incarcerated men who volun…
- Lilly's Lebrikizumab Plus Topical Corticosteroids Offer Improvement and Itch Relief in Atopic Dermatitishttps://practicaldermatology.com/news/lillys-lebrikizumab-plus-topical-corticosteroids-offer-improvement-and-itch-relief-in-atopic-dermatitis/2461015/Lebrikizumab, an IL-13 inhibitor, significantly improved disease severity when combined with topical corticosteroids (TCS) in people with moderate-to-severe atopic dermatitis (AD) in Eli Lilly and Company's third pivotal Phase 3 trial (ADhere). By Week 16, the study met all primary and key secondar…